A. Giant Cell Arteritis, Polymyalgia Rheumatica, and Takayasu’s Arteritis
  • Cornelia M. Weyand
  • JÖrg J. Goronzy


  • Giant cell arteritis (GCA) and Takayasu’s arteritis (TA) are prototypes of large vessel vasculitis, tending to involve the aorta and its branches.

  • Giant cell arteritis predominantly affects the secondto fifth-order aortic branches, often in the extracranial arteries of the head.

  • Giant cell arteritis occurs exclusively among individuals who are 50 years of age or older. The mean age at diagnosis onset is approximately 72.

  • In TA, the aorta and its major branches are the prime disease targets.

  • Both GCA and TA are associated with granulomatous inflammation within the blood vessel wall.

  • In both GCA and TA, clinical symptoms of vascular inflammation and vascular insufficiency are usually accompanied or preceded by a systemic inflammatory process.

  • Visual loss is the most feared complication of GCA. Visual loss may occur through the syndrome of anterior ischemic optic neuropathy, caused by narrowing of the posterior ciliary artery and other vessels to the eye.

  • The diagnosis of GCA is made usually by biopsy of the temporal artery.

  • Polymyalgia rheumatica (PMR), a syndrome of muscle pain and stiffness in the neck, shoulders, and hips, often occurs with GCA but can occur independently.

  • ■ Glucocorticoids are the cornerstone of treatment for GCA, TA, and PMR. Isolated PMR requires a lower dose of prednisone for disease control.


Magnetic Resonance Angiography Giant Cell Arteritis Human Leukocyte Antigen Class Multinucleated Giant Cell Temporal Artery 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Hunder GG. Giant cell arteritis and polymyalgia rheumatica. Med Clin North Am 1997;811:195–219.CrossRefGoogle Scholar
  2. 2.
    Weyand CM, Goronzy JJ. Medium-and large-vessel vasculitis. N Engl J Med 2003;349:160–169.PubMedCrossRefGoogle Scholar
  3. 3.
    Ma-Krupa W, Jeon MS, Spoerl S, et al. Activation of arterial wall dendritic cells and breakdown of self-tolerance in giant cell arteritis. J Exp Med 2004;1992:173–183.CrossRefGoogle Scholar
  4. 4.
    Weyand CM, Wagner AD, Bjornsson J, et al. Correlation of the topographical arrangement and the functional pattern of tissue-infiltrating macrophages in giant cell arteritis. J Clin Invest 1996;987:1642–1649.Google Scholar
  5. 5.
    Rittner HL, Kaiser M, Brack A, et al. Tissue-destructive macrophages in giant cell arteritis. Circ Res 1999;849:1050–1058.Google Scholar
  6. 6.
    Weyand CM, Tetzlaff N, Bjornsson J, et al. Disease patterns and tissue cytokine profiles in giant cell arteritis. Arthritis Rheum 1997;401:19–26.CrossRefGoogle Scholar
  7. 7.
    Weyand CM, Goronzy JJ. Arterial wall injury in giant cell arteritis. Arthritis Rheum 1999;425:844–853.CrossRefGoogle Scholar
  8. 8.
    Kaiser M, Weyand CM, Bjornsson J, et al. Platelet-derived growth factor, intimal hyperplasia, and ischemic complications in giant cell arteritis. Arthritis Rheum 1998;414:623–633.CrossRefGoogle Scholar
  9. 9.
    Kaiser M, Younge B, Bjornsson J, et al. Formation of new vasa vasorum in vasculitis. Production of angiogenic cytokines by multinucleated giant cells. Am J Pathol 1999;1553:765–774.Google Scholar
  10. 10.
    Rittner HL, Hafner V, Klimiuk PA, et al. Aldose reductase functions as a detoxification system for lipid peroxidation products in vasculitis. J Clin Invest 1999;1037:1007–1013.Google Scholar
  11. 11.
    Weyand CM, Goronzy JJ. Giant-cell arteritis and polymyalgia rheumatica. Ann Intern Med 2003;1396:505–515.Google Scholar
  12. 12.
    Brack A, Martinez-Taboada V, Stanson A, et al. Disease pattern in cranial and large-vessel giant cell arteritis. Arthritis Rheum 1999;422:311–317.CrossRefGoogle Scholar
  13. 13.
    Nuenninghoff DM, Hunder GG, Christianson TJ, et al. Incidence and predictors of large-artery complication (aortic aneurysm, aortic dissection, and/or large-artery stenosis) in patients with giant cell arteritis: a populationbased study over 50 years. Arthritis Rheum 2003;4812:3522–3531.CrossRefGoogle Scholar
  14. 14.
    Evans JM, O’Fallon WM, Hunder GG. Increased incidence of aortic aneurysm and dissection in giant cell (temporal) arteritis. A population-based study. Ann Intern Med 1995;1227:502–507.Google Scholar
  15. 15.
    Smetana GW, Shmerling RH. Does this patient have temporal arteritis? JAMA 2002;2871:92–101.CrossRefGoogle Scholar
  16. 16.
    Weyand CM, Fulbright JW, Hunder GG, et al. Treatment of giant cell arteritis: interleukin-6 as a biologic marker of disease activity. Arthritis Rheum 2000;435:1041–1048.CrossRefGoogle Scholar
  17. 17.
    Seo P, Stone JH. Large-vessel vasculitis. Arthritis Rheum 2004;511:128–139.CrossRefGoogle Scholar
  18. 18.
    Salvarani C, Silingardi M, Ghirarduzzi A, et al. Is duplex ultrasonography useful for the diagnosis of giant-cell arteritis? Ann Intern Med 2002;1374:232–238.Google Scholar
  19. 19.
    Hayreh SS, Zimmerman B, Kardon RH. Visual improvement with corticosteroid therapy in giant cell arteritis. Report of a large study and review of literature. Acta Ophthalmol Scand 2002;804:355–367.CrossRefGoogle Scholar
  20. 20.
    Hoffman GS, Cinta-Cid M, Hellmann D, et al. A multicenter placebo-controlled study of methotrexate (MTX) in giant cell ateritis (GCA). Arthritis Rheum 2000;43: S115.CrossRefGoogle Scholar
  21. 21.
    Hoffman GS, Cinta-Cid M, Rendt KE, et al. Prednisone and infliximab for giant cell arteritis: a randomized, double-blind, placebo-controlled, multicenter study of efficacy and safety. Ann Int Med 2007;146:621–630.PubMedGoogle Scholar
  22. 22.
    Mazlumzadeh M, Hunder GG, Easley KA, et al. Treatment of giant cell arteritis: induction therapy with high dose glucocorticoids. Arthritis Rheum 2006;54:3310–3318.PubMedCrossRefGoogle Scholar
  23. 23.
    Nesher G, Berkun Y, Mates M, et al. Low-dose aspirin and prevention of cranial ischemic complications in giant cell arteritis. Arthritis Rheum 2004;50:1332–1337.PubMedCrossRefGoogle Scholar
  24. 24.
    Salvarani C, Cantini F, Boiardi L, et al. Polymyalgia rheumatica and giant-cell arteritis. N Engl J Med 2002;3474:261–271.CrossRefGoogle Scholar
  25. 25.
    Weyand CM, Hicok KC, Hunder GG, et al. Tissue cytokine patterns in patients with polymyalgia rheumatica and giant cell arteritis. Ann Intern Med 1994;1217:484–491.Google Scholar
  26. 26.
    Weyand CM, Fulbright JW, Evans JM, et al. Corticosteroid requirements in polymyalgia rheumatica. Arch Intern Med 1999;1596:577–584.CrossRefGoogle Scholar
  27. 27.
    Salvarani C, Cantini F, Olivieri I, et al. Proximal bursitis in active polymyalgia rheumatica. Ann Intern Med 1997;1271:27–31.Google Scholar
  28. 28.
    Kerr GS. Takayasu’s arteritis. Rheum Dis Clin North Am 1995;214:1041–1058.Google Scholar
  29. 29.
    Numano F. Differences in clinical presentation and outcome in different countries for Takayasu’s arteritis. Curr Opin Rheumatol 1997;91:12–15.CrossRefGoogle Scholar
  30. 30.
    Seko Y. Takayasu arteritis: insights into immunopathology. Jpn Heart J 2000;411:15–26.CrossRefGoogle Scholar
  31. 31.
    Kimura A, Kitamura H, Date Y, et al. Comprehensive analysis of HLA genes in Takayasu arteritis in Japan. Int J Cardiol 1996;54(Suppl):S61–S69.PubMedCrossRefGoogle Scholar
  32. 32.
    Kissin EY, Merkel PA. Diagnostic imaging in Takayasu arteritis. Curr Opin Rheumatol 2004;161:31–37.CrossRefGoogle Scholar
  33. 33.
    Liang P, Hoffman GS. Advances in the medical and surgical treatment of Takayasu arteritis. Curr Opin Rheumatol 2005;171:16–24.CrossRefGoogle Scholar
  34. 34.
    Kerr GS, Hallahan CW, Giordano J, et al. Takayasu arteritis. Ann Intern Med 1994;12011:919–929.Google Scholar
  35. 35.
    Langford CA, Sneller MC, Hoffman GS. Methotrexate use in systemic vasculitis. Rheum Dis Clin North Am 1997;234:841–853.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2008

Authors and Affiliations

  • Cornelia M. Weyand
    • 1
  • JÖrg J. Goronzy
    • 1
  1. 1.Kathleen B. and Mason I. Lowance Center for Human Immunology, Department of MedicineEmory University School of MedicineAtlantaUSA

Personalised recommendations